Compare FTFT & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | PMCB |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.3M |
| IPO Year | 2008 | 2001 |
| Metric | FTFT | PMCB |
|---|---|---|
| Price | $0.82 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 106.3K | ★ 125.6K |
| Earning Date | 05-19-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.45 | $0.53 |
| 52 Week High | $3.88 | $1.51 |
| Indicator | FTFT | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 35.35 |
| Support Level | $0.50 | $0.55 |
| Resistance Level | $1.32 | $0.77 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 13.37 | 29.99 |
Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.